nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosentan—EDNRB—breast cancer	0.372	0.879	CbGaD
Bosentan—CYP3A4—breast cancer	0.0511	0.121	CbGaD
Bosentan—ABCB11—Tamoxifen—breast cancer	0.0444	0.133	CbGbCtD
Bosentan—ABCB11—Paclitaxel—breast cancer	0.0346	0.103	CbGbCtD
Bosentan—ABCB11—Vinblastine—breast cancer	0.0303	0.0907	CbGbCtD
Bosentan—CYP2C9—Anastrozole—breast cancer	0.0235	0.0703	CbGbCtD
Bosentan—ABCB11—Doxorubicin—breast cancer	0.0186	0.0557	CbGbCtD
Bosentan—CYP3A4—Exemestane—breast cancer	0.018	0.0539	CbGbCtD
Bosentan—CYP2C9—Idarubicin—breast cancer	0.0178	0.0532	CbGbCtD
Bosentan—CYP3A4—Letrozole—breast cancer	0.0153	0.0458	CbGbCtD
Bosentan—CYP3A4—Anastrozole—breast cancer	0.0137	0.0409	CbGbCtD
Bosentan—CYP3A4—Toremifene—breast cancer	0.0125	0.0374	CbGbCtD
Bosentan—CYP3A4—Fulvestrant—breast cancer	0.0116	0.0347	CbGbCtD
Bosentan—CYP3A4—Thiotepa—breast cancer	0.0103	0.031	CbGbCtD
Bosentan—CYP2C9—Capecitabine—breast cancer	0.00975	0.0292	CbGbCtD
Bosentan—CYP3A4—Ixabepilone—breast cancer	0.00946	0.0283	CbGbCtD
Bosentan—CYP3A4—Lapatinib—breast cancer	0.00911	0.0273	CbGbCtD
Bosentan—CYP2C9—Tamoxifen—breast cancer	0.00784	0.0235	CbGbCtD
Bosentan—CYP3A4—Raloxifene—breast cancer	0.0069	0.0207	CbGbCtD
Bosentan—CYP2C9—Paclitaxel—breast cancer	0.0061	0.0183	CbGbCtD
Bosentan—CYP2C9—Fluorouracil—breast cancer	0.00578	0.0173	CbGbCtD
Bosentan—CYP3A4—Vinorelbine—breast cancer	0.00505	0.0151	CbGbCtD
Bosentan—CYP3A4—Tamoxifen—breast cancer	0.00456	0.0136	CbGbCtD
Bosentan—CYP3A4—Mitoxantrone—breast cancer	0.00445	0.0133	CbGbCtD
Bosentan—CYP3A4—Paclitaxel—breast cancer	0.00355	0.0106	CbGbCtD
Bosentan—CYP3A4—Irinotecan—breast cancer	0.0035	0.0105	CbGbCtD
Bosentan—CYP3A4—Vinblastine—breast cancer	0.00311	0.00932	CbGbCtD
Bosentan—EDNRB—mammary gland—breast cancer	0.00268	0.105	CbGeAlD
Bosentan—CYP3A4—Docetaxel—breast cancer	0.00257	0.00768	CbGbCtD
Bosentan—EDNRB—nipple—breast cancer	0.00221	0.0868	CbGeAlD
Bosentan—EDNRA—mammary gland—breast cancer	0.00221	0.0867	CbGeAlD
Bosentan—CYP3A4—Doxorubicin—breast cancer	0.00191	0.00573	CbGbCtD
Bosentan—EDNRA—nipple—breast cancer	0.00183	0.0718	CbGeAlD
Bosentan—EDNRB—endometrium—breast cancer	0.00134	0.0524	CbGeAlD
Bosentan—EDNRB—uterus—breast cancer	0.00123	0.0483	CbGeAlD
Bosentan—EDNRB—pituitary gland—breast cancer	0.00121	0.0474	CbGeAlD
Bosentan—EDNRB—adipose tissue—breast cancer	0.0012	0.0472	CbGeAlD
Bosentan—EDNRA—endometrium—breast cancer	0.00111	0.0433	CbGeAlD
Bosentan—EDNRB—adrenal gland—breast cancer	0.00108	0.0424	CbGeAlD
Bosentan—EDNRA—uterus—breast cancer	0.00102	0.0399	CbGeAlD
Bosentan—EDNRB—female gonad—breast cancer	0.00101	0.0395	CbGeAlD
Bosentan—EDNRA—pituitary gland—breast cancer	0.001	0.0392	CbGeAlD
Bosentan—EDNRA—adipose tissue—breast cancer	0.000996	0.039	CbGeAlD
Bosentan—EDNRA—adrenal gland—breast cancer	0.000893	0.035	CbGeAlD
Bosentan—EDNRA—female gonad—breast cancer	0.000833	0.0327	CbGeAlD
Bosentan—ABCB11—endocrine gland—breast cancer	0.000757	0.0297	CbGeAlD
Bosentan—CYP2C9—mammary gland—breast cancer	0.000732	0.0287	CbGeAlD
Bosentan—EDNRB—lymph node—breast cancer	0.000648	0.0254	CbGeAlD
Bosentan—EDNRA—lymph node—breast cancer	0.000535	0.021	CbGeAlD
Bosentan—CYP2C9—female reproductive system—breast cancer	0.000303	0.0119	CbGeAlD
Bosentan—CYP2C9—endocrine gland—breast cancer	0.000256	0.01	CbGeAlD
Bosentan—CYP3A4—female reproductive system—breast cancer	0.000231	0.00906	CbGeAlD
Bosentan—CYP3A4—endocrine gland—breast cancer	0.000195	0.00766	CbGeAlD
Bosentan—Erythema multiforme—Epirubicin—breast cancer	2.38e-05	0.000158	CcSEcCtD
Bosentan—Vomiting—Gemcitabine—breast cancer	2.37e-05	0.000158	CcSEcCtD
Bosentan—Bradycardia—Doxorubicin—breast cancer	2.37e-05	0.000158	CcSEcCtD
Bosentan—Dyspnoea—Docetaxel—breast cancer	2.36e-05	0.000157	CcSEcCtD
Bosentan—Somnolence—Docetaxel—breast cancer	2.35e-05	0.000157	CcSEcCtD
Bosentan—Mental disorder—Methotrexate—breast cancer	2.35e-05	0.000157	CcSEcCtD
Bosentan—Rash—Gemcitabine—breast cancer	2.35e-05	0.000157	CcSEcCtD
Bosentan—Dermatitis—Gemcitabine—breast cancer	2.35e-05	0.000157	CcSEcCtD
Bosentan—Eye disorder—Epirubicin—breast cancer	2.35e-05	0.000156	CcSEcCtD
Bosentan—Tinnitus—Epirubicin—breast cancer	2.34e-05	0.000156	CcSEcCtD
Bosentan—Erythema—Methotrexate—breast cancer	2.34e-05	0.000156	CcSEcCtD
Bosentan—Malnutrition—Methotrexate—breast cancer	2.34e-05	0.000156	CcSEcCtD
Bosentan—Haemoglobin—Doxorubicin—breast cancer	2.34e-05	0.000156	CcSEcCtD
Bosentan—Headache—Gemcitabine—breast cancer	2.34e-05	0.000156	CcSEcCtD
Bosentan—Musculoskeletal discomfort—Capecitabine—breast cancer	2.34e-05	0.000156	CcSEcCtD
Bosentan—Flushing—Epirubicin—breast cancer	2.33e-05	0.000155	CcSEcCtD
Bosentan—Cardiac disorder—Epirubicin—breast cancer	2.33e-05	0.000155	CcSEcCtD
Bosentan—Vomiting—Fluorouracil—breast cancer	2.33e-05	0.000155	CcSEcCtD
Bosentan—Dyspepsia—Docetaxel—breast cancer	2.33e-05	0.000155	CcSEcCtD
Bosentan—Haemorrhage—Doxorubicin—breast cancer	2.33e-05	0.000155	CcSEcCtD
Bosentan—Hepatitis—Doxorubicin—breast cancer	2.33e-05	0.000155	CcSEcCtD
Bosentan—Insomnia—Capecitabine—breast cancer	2.32e-05	0.000154	CcSEcCtD
Bosentan—Hypoaesthesia—Doxorubicin—breast cancer	2.31e-05	0.000154	CcSEcCtD
Bosentan—Rash—Fluorouracil—breast cancer	2.31e-05	0.000154	CcSEcCtD
Bosentan—Dermatitis—Fluorouracil—breast cancer	2.31e-05	0.000154	CcSEcCtD
Bosentan—Paraesthesia—Capecitabine—breast cancer	2.3e-05	0.000153	CcSEcCtD
Bosentan—Decreased appetite—Docetaxel—breast cancer	2.3e-05	0.000153	CcSEcCtD
Bosentan—Hypersensitivity—Paclitaxel—breast cancer	2.3e-05	0.000153	CcSEcCtD
Bosentan—Headache—Fluorouracil—breast cancer	2.3e-05	0.000153	CcSEcCtD
Bosentan—Urinary tract disorder—Doxorubicin—breast cancer	2.3e-05	0.000153	CcSEcCtD
Bosentan—Oedema peripheral—Doxorubicin—breast cancer	2.29e-05	0.000153	CcSEcCtD
Bosentan—Gastrointestinal disorder—Docetaxel—breast cancer	2.29e-05	0.000152	CcSEcCtD
Bosentan—Dyspnoea—Capecitabine—breast cancer	2.29e-05	0.000152	CcSEcCtD
Bosentan—Fatigue—Docetaxel—breast cancer	2.28e-05	0.000152	CcSEcCtD
Bosentan—Angiopathy—Epirubicin—breast cancer	2.28e-05	0.000152	CcSEcCtD
Bosentan—Urethral disorder—Doxorubicin—breast cancer	2.28e-05	0.000152	CcSEcCtD
Bosentan—Nausea—Irinotecan—breast cancer	2.28e-05	0.000152	CcSEcCtD
Bosentan—Nausea—Mitoxantrone—breast cancer	2.28e-05	0.000152	CcSEcCtD
Bosentan—Immune system disorder—Epirubicin—breast cancer	2.27e-05	0.000151	CcSEcCtD
Bosentan—Mediastinal disorder—Epirubicin—breast cancer	2.27e-05	0.000151	CcSEcCtD
Bosentan—Pain—Docetaxel—breast cancer	2.26e-05	0.000151	CcSEcCtD
Bosentan—Constipation—Docetaxel—breast cancer	2.26e-05	0.000151	CcSEcCtD
Bosentan—Back pain—Methotrexate—breast cancer	2.26e-05	0.000151	CcSEcCtD
Bosentan—Dyspepsia—Capecitabine—breast cancer	2.26e-05	0.00015	CcSEcCtD
Bosentan—Chills—Epirubicin—breast cancer	2.26e-05	0.00015	CcSEcCtD
Bosentan—Asthenia—Paclitaxel—breast cancer	2.24e-05	0.000149	CcSEcCtD
Bosentan—Decreased appetite—Capecitabine—breast cancer	2.23e-05	0.000148	CcSEcCtD
Bosentan—Nausea—Gemcitabine—breast cancer	2.22e-05	0.000148	CcSEcCtD
Bosentan—Gastrointestinal disorder—Capecitabine—breast cancer	2.21e-05	0.000147	CcSEcCtD
Bosentan—Fatigue—Capecitabine—breast cancer	2.21e-05	0.000147	CcSEcCtD
Bosentan—Pruritus—Paclitaxel—breast cancer	2.21e-05	0.000147	CcSEcCtD
Bosentan—Vision blurred—Methotrexate—breast cancer	2.2e-05	0.000147	CcSEcCtD
Bosentan—Mental disorder—Epirubicin—breast cancer	2.2e-05	0.000147	CcSEcCtD
Bosentan—Erythema multiforme—Doxorubicin—breast cancer	2.2e-05	0.000146	CcSEcCtD
Bosentan—Constipation—Capecitabine—breast cancer	2.19e-05	0.000146	CcSEcCtD
Bosentan—Pain—Capecitabine—breast cancer	2.19e-05	0.000146	CcSEcCtD
Bosentan—Erythema—Epirubicin—breast cancer	2.19e-05	0.000146	CcSEcCtD
Bosentan—Malnutrition—Epirubicin—breast cancer	2.19e-05	0.000146	CcSEcCtD
Bosentan—Nausea—Fluorouracil—breast cancer	2.18e-05	0.000145	CcSEcCtD
Bosentan—Eye disorder—Doxorubicin—breast cancer	2.17e-05	0.000145	CcSEcCtD
Bosentan—Tinnitus—Doxorubicin—breast cancer	2.17e-05	0.000144	CcSEcCtD
Bosentan—Gastrointestinal pain—Docetaxel—breast cancer	2.17e-05	0.000144	CcSEcCtD
Bosentan—Anaemia—Methotrexate—breast cancer	2.16e-05	0.000144	CcSEcCtD
Bosentan—Cardiac disorder—Doxorubicin—breast cancer	2.16e-05	0.000144	CcSEcCtD
Bosentan—Flushing—Doxorubicin—breast cancer	2.16e-05	0.000144	CcSEcCtD
Bosentan—Flatulence—Epirubicin—breast cancer	2.16e-05	0.000144	CcSEcCtD
Bosentan—Diarrhoea—Paclitaxel—breast cancer	2.14e-05	0.000142	CcSEcCtD
Bosentan—Back pain—Epirubicin—breast cancer	2.12e-05	0.000141	CcSEcCtD
Bosentan—Angiopathy—Doxorubicin—breast cancer	2.11e-05	0.000141	CcSEcCtD
Bosentan—Muscle spasms—Epirubicin—breast cancer	2.1e-05	0.00014	CcSEcCtD
Bosentan—Immune system disorder—Doxorubicin—breast cancer	2.1e-05	0.00014	CcSEcCtD
Bosentan—Vertigo—Methotrexate—breast cancer	2.1e-05	0.00014	CcSEcCtD
Bosentan—Gastrointestinal pain—Capecitabine—breast cancer	2.1e-05	0.00014	CcSEcCtD
Bosentan—Mediastinal disorder—Doxorubicin—breast cancer	2.1e-05	0.00014	CcSEcCtD
Bosentan—Abdominal pain—Docetaxel—breast cancer	2.09e-05	0.000139	CcSEcCtD
Bosentan—Body temperature increased—Docetaxel—breast cancer	2.09e-05	0.000139	CcSEcCtD
Bosentan—Leukopenia—Methotrexate—breast cancer	2.09e-05	0.000139	CcSEcCtD
Bosentan—Chills—Doxorubicin—breast cancer	2.09e-05	0.000139	CcSEcCtD
Bosentan—Dizziness—Paclitaxel—breast cancer	2.07e-05	0.000138	CcSEcCtD
Bosentan—Vision blurred—Epirubicin—breast cancer	2.06e-05	0.000137	CcSEcCtD
Bosentan—Cough—Methotrexate—breast cancer	2.04e-05	0.000136	CcSEcCtD
Bosentan—Mental disorder—Doxorubicin—breast cancer	2.04e-05	0.000136	CcSEcCtD
Bosentan—Urticaria—Capecitabine—breast cancer	2.04e-05	0.000136	CcSEcCtD
Bosentan—Abdominal pain—Capecitabine—breast cancer	2.03e-05	0.000135	CcSEcCtD
Bosentan—Body temperature increased—Capecitabine—breast cancer	2.03e-05	0.000135	CcSEcCtD
Bosentan—Erythema—Doxorubicin—breast cancer	2.03e-05	0.000135	CcSEcCtD
Bosentan—Malnutrition—Doxorubicin—breast cancer	2.03e-05	0.000135	CcSEcCtD
Bosentan—Anaemia—Epirubicin—breast cancer	2.02e-05	0.000135	CcSEcCtD
Bosentan—Flatulence—Doxorubicin—breast cancer	2e-05	0.000133	CcSEcCtD
Bosentan—Chest pain—Methotrexate—breast cancer	1.99e-05	0.000133	CcSEcCtD
Bosentan—Arthralgia—Methotrexate—breast cancer	1.99e-05	0.000133	CcSEcCtD
Bosentan—Vomiting—Paclitaxel—breast cancer	1.99e-05	0.000132	CcSEcCtD
Bosentan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	1.98e-05	0.000132	CcSEcCtD
Bosentan—Rash—Paclitaxel—breast cancer	1.97e-05	0.000131	CcSEcCtD
Bosentan—Dermatitis—Paclitaxel—breast cancer	1.97e-05	0.000131	CcSEcCtD
Bosentan—Discomfort—Methotrexate—breast cancer	1.97e-05	0.000131	CcSEcCtD
Bosentan—Vertigo—Epirubicin—breast cancer	1.97e-05	0.000131	CcSEcCtD
Bosentan—Syncope—Epirubicin—breast cancer	1.96e-05	0.000131	CcSEcCtD
Bosentan—Leukopenia—Epirubicin—breast cancer	1.96e-05	0.00013	CcSEcCtD
Bosentan—Back pain—Doxorubicin—breast cancer	1.96e-05	0.00013	CcSEcCtD
Bosentan—Headache—Paclitaxel—breast cancer	1.96e-05	0.00013	CcSEcCtD
Bosentan—Hypersensitivity—Docetaxel—breast cancer	1.95e-05	0.00013	CcSEcCtD
Bosentan—Muscle spasms—Doxorubicin—breast cancer	1.95e-05	0.00013	CcSEcCtD
Bosentan—Palpitations—Epirubicin—breast cancer	1.93e-05	0.000129	CcSEcCtD
Bosentan—Loss of consciousness—Epirubicin—breast cancer	1.92e-05	0.000128	CcSEcCtD
Bosentan—Cough—Epirubicin—breast cancer	1.91e-05	0.000127	CcSEcCtD
Bosentan—Anaphylactic shock—Methotrexate—breast cancer	1.91e-05	0.000127	CcSEcCtD
Bosentan—Vision blurred—Doxorubicin—breast cancer	1.91e-05	0.000127	CcSEcCtD
Bosentan—Asthenia—Docetaxel—breast cancer	1.9e-05	0.000127	CcSEcCtD
Bosentan—Infection—Methotrexate—breast cancer	1.9e-05	0.000126	CcSEcCtD
Bosentan—Hypersensitivity—Capecitabine—breast cancer	1.89e-05	0.000126	CcSEcCtD
Bosentan—Pruritus—Docetaxel—breast cancer	1.87e-05	0.000125	CcSEcCtD
Bosentan—Nervous system disorder—Methotrexate—breast cancer	1.87e-05	0.000125	CcSEcCtD
Bosentan—Anaemia—Doxorubicin—breast cancer	1.87e-05	0.000125	CcSEcCtD
Bosentan—Thrombocytopenia—Methotrexate—breast cancer	1.87e-05	0.000124	CcSEcCtD
Bosentan—Arthralgia—Epirubicin—breast cancer	1.86e-05	0.000124	CcSEcCtD
Bosentan—Chest pain—Epirubicin—breast cancer	1.86e-05	0.000124	CcSEcCtD
Bosentan—Anxiety—Epirubicin—breast cancer	1.86e-05	0.000124	CcSEcCtD
Bosentan—Nausea—Paclitaxel—breast cancer	1.86e-05	0.000124	CcSEcCtD
Bosentan—Skin disorder—Methotrexate—breast cancer	1.85e-05	0.000123	CcSEcCtD
Bosentan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	1.85e-05	0.000123	CcSEcCtD
Bosentan—Hyperhidrosis—Methotrexate—breast cancer	1.85e-05	0.000123	CcSEcCtD
Bosentan—Discomfort—Epirubicin—breast cancer	1.84e-05	0.000123	CcSEcCtD
Bosentan—Asthenia—Capecitabine—breast cancer	1.84e-05	0.000123	CcSEcCtD
Bosentan—Dry mouth—Epirubicin—breast cancer	1.82e-05	0.000121	CcSEcCtD
Bosentan—Vertigo—Doxorubicin—breast cancer	1.82e-05	0.000121	CcSEcCtD
Bosentan—Anorexia—Methotrexate—breast cancer	1.82e-05	0.000121	CcSEcCtD
Bosentan—Syncope—Doxorubicin—breast cancer	1.82e-05	0.000121	CcSEcCtD
Bosentan—Pruritus—Capecitabine—breast cancer	1.81e-05	0.000121	CcSEcCtD
Bosentan—Leukopenia—Doxorubicin—breast cancer	1.81e-05	0.000121	CcSEcCtD
Bosentan—Diarrhoea—Docetaxel—breast cancer	1.81e-05	0.000121	CcSEcCtD
Bosentan—Palpitations—Doxorubicin—breast cancer	1.79e-05	0.000119	CcSEcCtD
Bosentan—Anaphylactic shock—Epirubicin—breast cancer	1.79e-05	0.000119	CcSEcCtD
Bosentan—Oedema—Epirubicin—breast cancer	1.79e-05	0.000119	CcSEcCtD
Bosentan—Hypotension—Methotrexate—breast cancer	1.78e-05	0.000119	CcSEcCtD
Bosentan—Loss of consciousness—Doxorubicin—breast cancer	1.78e-05	0.000119	CcSEcCtD
Bosentan—Infection—Epirubicin—breast cancer	1.77e-05	0.000118	CcSEcCtD
Bosentan—Cough—Doxorubicin—breast cancer	1.77e-05	0.000118	CcSEcCtD
Bosentan—Shock—Epirubicin—breast cancer	1.76e-05	0.000117	CcSEcCtD
Bosentan—Diarrhoea—Capecitabine—breast cancer	1.75e-05	0.000117	CcSEcCtD
Bosentan—Nervous system disorder—Epirubicin—breast cancer	1.75e-05	0.000117	CcSEcCtD
Bosentan—Dizziness—Docetaxel—breast cancer	1.75e-05	0.000117	CcSEcCtD
Bosentan—Thrombocytopenia—Epirubicin—breast cancer	1.75e-05	0.000116	CcSEcCtD
Bosentan—Tachycardia—Epirubicin—breast cancer	1.74e-05	0.000116	CcSEcCtD
Bosentan—Musculoskeletal discomfort—Methotrexate—breast cancer	1.74e-05	0.000116	CcSEcCtD
Bosentan—Skin disorder—Epirubicin—breast cancer	1.74e-05	0.000116	CcSEcCtD
Bosentan—Hyperhidrosis—Epirubicin—breast cancer	1.73e-05	0.000115	CcSEcCtD
Bosentan—Insomnia—Methotrexate—breast cancer	1.73e-05	0.000115	CcSEcCtD
Bosentan—Arthralgia—Doxorubicin—breast cancer	1.72e-05	0.000115	CcSEcCtD
Bosentan—Chest pain—Doxorubicin—breast cancer	1.72e-05	0.000115	CcSEcCtD
Bosentan—Anxiety—Doxorubicin—breast cancer	1.72e-05	0.000114	CcSEcCtD
Bosentan—Paraesthesia—Methotrexate—breast cancer	1.71e-05	0.000114	CcSEcCtD
Bosentan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	1.71e-05	0.000114	CcSEcCtD
Bosentan—Discomfort—Doxorubicin—breast cancer	1.7e-05	0.000113	CcSEcCtD
Bosentan—Anorexia—Epirubicin—breast cancer	1.7e-05	0.000113	CcSEcCtD
Bosentan—Dyspnoea—Methotrexate—breast cancer	1.7e-05	0.000113	CcSEcCtD
Bosentan—Somnolence—Methotrexate—breast cancer	1.7e-05	0.000113	CcSEcCtD
Bosentan—Dizziness—Capecitabine—breast cancer	1.7e-05	0.000113	CcSEcCtD
Bosentan—Dry mouth—Doxorubicin—breast cancer	1.69e-05	0.000112	CcSEcCtD
Bosentan—Vomiting—Docetaxel—breast cancer	1.68e-05	0.000112	CcSEcCtD
Bosentan—Dyspepsia—Methotrexate—breast cancer	1.68e-05	0.000112	CcSEcCtD
Bosentan—Rash—Docetaxel—breast cancer	1.67e-05	0.000111	CcSEcCtD
Bosentan—Hypotension—Epirubicin—breast cancer	1.67e-05	0.000111	CcSEcCtD
Bosentan—Dermatitis—Docetaxel—breast cancer	1.67e-05	0.000111	CcSEcCtD
Bosentan—Decreased appetite—Methotrexate—breast cancer	1.66e-05	0.00011	CcSEcCtD
Bosentan—Headache—Docetaxel—breast cancer	1.66e-05	0.00011	CcSEcCtD
Bosentan—Oedema—Doxorubicin—breast cancer	1.65e-05	0.00011	CcSEcCtD
Bosentan—Anaphylactic shock—Doxorubicin—breast cancer	1.65e-05	0.00011	CcSEcCtD
Bosentan—Gastrointestinal disorder—Methotrexate—breast cancer	1.65e-05	0.00011	CcSEcCtD
Bosentan—Fatigue—Methotrexate—breast cancer	1.65e-05	0.00011	CcSEcCtD
Bosentan—Infection—Doxorubicin—breast cancer	1.64e-05	0.000109	CcSEcCtD
Bosentan—Pain—Methotrexate—breast cancer	1.63e-05	0.000109	CcSEcCtD
Bosentan—Vomiting—Capecitabine—breast cancer	1.63e-05	0.000109	CcSEcCtD
Bosentan—Musculoskeletal discomfort—Epirubicin—breast cancer	1.63e-05	0.000108	CcSEcCtD
Bosentan—Shock—Doxorubicin—breast cancer	1.63e-05	0.000108	CcSEcCtD
Bosentan—Nervous system disorder—Doxorubicin—breast cancer	1.62e-05	0.000108	CcSEcCtD
Bosentan—Thrombocytopenia—Doxorubicin—breast cancer	1.62e-05	0.000108	CcSEcCtD
Bosentan—Rash—Capecitabine—breast cancer	1.62e-05	0.000108	CcSEcCtD
Bosentan—Insomnia—Epirubicin—breast cancer	1.62e-05	0.000108	CcSEcCtD
Bosentan—Dermatitis—Capecitabine—breast cancer	1.62e-05	0.000108	CcSEcCtD
Bosentan—Tachycardia—Doxorubicin—breast cancer	1.61e-05	0.000107	CcSEcCtD
Bosentan—Headache—Capecitabine—breast cancer	1.61e-05	0.000107	CcSEcCtD
Bosentan—Skin disorder—Doxorubicin—breast cancer	1.61e-05	0.000107	CcSEcCtD
Bosentan—Paraesthesia—Epirubicin—breast cancer	1.6e-05	0.000107	CcSEcCtD
Bosentan—Hyperhidrosis—Doxorubicin—breast cancer	1.6e-05	0.000106	CcSEcCtD
Bosentan—Dyspnoea—Epirubicin—breast cancer	1.59e-05	0.000106	CcSEcCtD
Bosentan—Somnolence—Epirubicin—breast cancer	1.59e-05	0.000106	CcSEcCtD
Bosentan—Anorexia—Doxorubicin—breast cancer	1.58e-05	0.000105	CcSEcCtD
Bosentan—Nausea—Docetaxel—breast cancer	1.57e-05	0.000105	CcSEcCtD
Bosentan—Dyspepsia—Epirubicin—breast cancer	1.57e-05	0.000105	CcSEcCtD
Bosentan—Gastrointestinal pain—Methotrexate—breast cancer	1.56e-05	0.000104	CcSEcCtD
Bosentan—Decreased appetite—Epirubicin—breast cancer	1.55e-05	0.000103	CcSEcCtD
Bosentan—Hypotension—Doxorubicin—breast cancer	1.54e-05	0.000103	CcSEcCtD
Bosentan—Gastrointestinal disorder—Epirubicin—breast cancer	1.54e-05	0.000103	CcSEcCtD
Bosentan—Fatigue—Epirubicin—breast cancer	1.54e-05	0.000103	CcSEcCtD
Bosentan—Pain—Epirubicin—breast cancer	1.53e-05	0.000102	CcSEcCtD
Bosentan—Constipation—Epirubicin—breast cancer	1.53e-05	0.000102	CcSEcCtD
Bosentan—Nausea—Capecitabine—breast cancer	1.52e-05	0.000101	CcSEcCtD
Bosentan—Urticaria—Methotrexate—breast cancer	1.52e-05	0.000101	CcSEcCtD
Bosentan—Body temperature increased—Methotrexate—breast cancer	1.51e-05	0.0001	CcSEcCtD
Bosentan—Abdominal pain—Methotrexate—breast cancer	1.51e-05	0.0001	CcSEcCtD
Bosentan—Musculoskeletal discomfort—Doxorubicin—breast cancer	1.51e-05	0.0001	CcSEcCtD
Bosentan—Insomnia—Doxorubicin—breast cancer	1.49e-05	9.95e-05	CcSEcCtD
Bosentan—Paraesthesia—Doxorubicin—breast cancer	1.48e-05	9.88e-05	CcSEcCtD
Bosentan—Dyspnoea—Doxorubicin—breast cancer	1.47e-05	9.81e-05	CcSEcCtD
Bosentan—Somnolence—Doxorubicin—breast cancer	1.47e-05	9.78e-05	CcSEcCtD
Bosentan—Gastrointestinal pain—Epirubicin—breast cancer	1.46e-05	9.73e-05	CcSEcCtD
Bosentan—Dyspepsia—Doxorubicin—breast cancer	1.45e-05	9.69e-05	CcSEcCtD
Bosentan—Decreased appetite—Doxorubicin—breast cancer	1.44e-05	9.57e-05	CcSEcCtD
Bosentan—Gastrointestinal disorder—Doxorubicin—breast cancer	1.43e-05	9.5e-05	CcSEcCtD
Bosentan—Fatigue—Doxorubicin—breast cancer	1.43e-05	9.49e-05	CcSEcCtD
Bosentan—Urticaria—Epirubicin—breast cancer	1.42e-05	9.45e-05	CcSEcCtD
Bosentan—Constipation—Doxorubicin—breast cancer	1.41e-05	9.41e-05	CcSEcCtD
Bosentan—Pain—Doxorubicin—breast cancer	1.41e-05	9.41e-05	CcSEcCtD
Bosentan—Body temperature increased—Epirubicin—breast cancer	1.41e-05	9.4e-05	CcSEcCtD
Bosentan—Abdominal pain—Epirubicin—breast cancer	1.41e-05	9.4e-05	CcSEcCtD
Bosentan—Hypersensitivity—Methotrexate—breast cancer	1.41e-05	9.36e-05	CcSEcCtD
Bosentan—Asthenia—Methotrexate—breast cancer	1.37e-05	9.12e-05	CcSEcCtD
Bosentan—Gastrointestinal pain—Doxorubicin—breast cancer	1.35e-05	9e-05	CcSEcCtD
Bosentan—Pruritus—Methotrexate—breast cancer	1.35e-05	8.99e-05	CcSEcCtD
Bosentan—Hypersensitivity—Epirubicin—breast cancer	1.32e-05	8.76e-05	CcSEcCtD
Bosentan—Urticaria—Doxorubicin—breast cancer	1.31e-05	8.74e-05	CcSEcCtD
Bosentan—Body temperature increased—Doxorubicin—breast cancer	1.31e-05	8.7e-05	CcSEcCtD
Bosentan—Abdominal pain—Doxorubicin—breast cancer	1.31e-05	8.7e-05	CcSEcCtD
Bosentan—Diarrhoea—Methotrexate—breast cancer	1.31e-05	8.7e-05	CcSEcCtD
Bosentan—Asthenia—Epirubicin—breast cancer	1.28e-05	8.53e-05	CcSEcCtD
Bosentan—Pruritus—Epirubicin—breast cancer	1.26e-05	8.42e-05	CcSEcCtD
Bosentan—Dizziness—Methotrexate—breast cancer	1.26e-05	8.41e-05	CcSEcCtD
Bosentan—Diarrhoea—Epirubicin—breast cancer	1.22e-05	8.14e-05	CcSEcCtD
Bosentan—Hypersensitivity—Doxorubicin—breast cancer	1.22e-05	8.11e-05	CcSEcCtD
Bosentan—Vomiting—Methotrexate—breast cancer	1.21e-05	8.08e-05	CcSEcCtD
Bosentan—Rash—Methotrexate—breast cancer	1.2e-05	8.01e-05	CcSEcCtD
Bosentan—Dermatitis—Methotrexate—breast cancer	1.2e-05	8.01e-05	CcSEcCtD
Bosentan—Headache—Methotrexate—breast cancer	1.2e-05	7.96e-05	CcSEcCtD
Bosentan—Asthenia—Doxorubicin—breast cancer	1.19e-05	7.9e-05	CcSEcCtD
Bosentan—Dizziness—Epirubicin—breast cancer	1.18e-05	7.87e-05	CcSEcCtD
Bosentan—Pruritus—Doxorubicin—breast cancer	1.17e-05	7.79e-05	CcSEcCtD
Bosentan—Vomiting—Epirubicin—breast cancer	1.14e-05	7.56e-05	CcSEcCtD
Bosentan—Nausea—Methotrexate—breast cancer	1.13e-05	7.55e-05	CcSEcCtD
Bosentan—Diarrhoea—Doxorubicin—breast cancer	1.13e-05	7.53e-05	CcSEcCtD
Bosentan—Rash—Epirubicin—breast cancer	1.13e-05	7.5e-05	CcSEcCtD
Bosentan—Dermatitis—Epirubicin—breast cancer	1.13e-05	7.49e-05	CcSEcCtD
Bosentan—Headache—Epirubicin—breast cancer	1.12e-05	7.45e-05	CcSEcCtD
Bosentan—Dizziness—Doxorubicin—breast cancer	1.09e-05	7.28e-05	CcSEcCtD
Bosentan—Nausea—Epirubicin—breast cancer	1.06e-05	7.07e-05	CcSEcCtD
Bosentan—Vomiting—Doxorubicin—breast cancer	1.05e-05	7e-05	CcSEcCtD
Bosentan—Rash—Doxorubicin—breast cancer	1.04e-05	6.94e-05	CcSEcCtD
Bosentan—Dermatitis—Doxorubicin—breast cancer	1.04e-05	6.93e-05	CcSEcCtD
Bosentan—Headache—Doxorubicin—breast cancer	1.04e-05	6.89e-05	CcSEcCtD
Bosentan—Nausea—Doxorubicin—breast cancer	9.82e-06	6.54e-05	CcSEcCtD
Bosentan—EDNRA—Signaling by GPCR—MAPK3—breast cancer	7.59e-06	0.000113	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—JUN—breast cancer	7.58e-06	0.000113	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CTNNB1—breast cancer	7.52e-06	0.000112	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—NDUFS3—breast cancer	7.5e-06	0.000112	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—BRAF—breast cancer	7.45e-06	0.000111	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—MMP9—breast cancer	7.37e-06	0.00011	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—NCOA1—breast cancer	7.35e-06	0.00011	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CDKN1A—breast cancer	7.34e-06	0.00011	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ALDH1A1—breast cancer	7.33e-06	0.00011	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ALDH7A1—breast cancer	7.33e-06	0.00011	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—PTEN—breast cancer	7.33e-06	0.00011	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—MTHFR—breast cancer	7.27e-06	0.000109	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—IGF1—breast cancer	7.25e-06	0.000108	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—breast cancer	7.25e-06	0.000108	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—AKT2—breast cancer	7.25e-06	0.000108	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—EGFR—breast cancer	7.22e-06	0.000108	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—MAPK8—breast cancer	7.17e-06	0.000107	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—AKT1—breast cancer	7.15e-06	0.000107	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CHST9—breast cancer	7.06e-06	0.000106	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—NME1—breast cancer	7.03e-06	0.000105	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ADSL—breast cancer	7.03e-06	0.000105	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—FHL2—breast cancer	7.03e-06	0.000105	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PHGDH—breast cancer	7.03e-06	0.000105	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—UMPS—breast cancer	7.03e-06	0.000105	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PIK3CD—breast cancer	6.96e-06	0.000104	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—PIK3CA—breast cancer	6.9e-06	0.000103	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—BRIP1—breast cancer	6.89e-06	0.000103	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—LDHB—breast cancer	6.89e-06	0.000103	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—HPSE—breast cancer	6.89e-06	0.000103	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—SERPINE1—breast cancer	6.89e-06	0.000103	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—KRAS—breast cancer	6.82e-06	0.000102	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—SRC—breast cancer	6.8e-06	0.000102	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—CAV1—breast cancer	6.7e-06	0.0001	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—COX11—breast cancer	6.69e-06	0.0001	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—VEGFA—breast cancer	6.62e-06	9.9e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—NOS3—breast cancer	6.58e-06	9.83e-05	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—STAT3—breast cancer	6.55e-06	9.8e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ABCC1—breast cancer	6.54e-06	9.77e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—HMMR—breast cancer	6.54e-06	9.77e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GSTA3—breast cancer	6.54e-06	9.77e-05	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	6.4e-06	9.57e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PPARGC1B—breast cancer	6.33e-06	9.46e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—PIK3CA—breast cancer	6.26e-06	9.37e-05	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—MAPK3—breast cancer	6.26e-06	9.36e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—MDM2—breast cancer	6.24e-06	9.33e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—RAF1—breast cancer	6.22e-06	9.3e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—RELA—breast cancer	6.19e-06	9.25e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—breast cancer	6.16e-06	9.22e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4A—breast cancer	6.16e-06	9.22e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—ERBB2—breast cancer	6.15e-06	9.2e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—SHMT1—breast cancer	6.12e-06	9.15e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CDA—breast cancer	6.12e-06	9.15e-05	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PIK3CG—breast cancer	6.1e-06	9.13e-05	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—MYC—breast cancer	6.09e-06	9.11e-05	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—TGFB1—breast cancer	6.07e-06	9.08e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PIK3CB—breast cancer	6.07e-06	9.08e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—MTOR—breast cancer	6.07e-06	9.08e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GSTA4—breast cancer	5.98e-06	8.94e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CA9—breast cancer	5.98e-06	8.94e-05	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—EGFR—breast cancer	5.96e-06	8.91e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—breast cancer	5.9e-06	8.83e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—SLCO1B1—breast cancer	5.89e-06	8.81e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—SLC2A5—breast cancer	5.89e-06	8.81e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—breast cancer	5.84e-06	8.74e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CXCL8—breast cancer	5.83e-06	8.72e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GPX2—breast cancer	5.83e-06	8.71e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GSTA2—breast cancer	5.83e-06	8.71e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—HRAS—breast cancer	5.79e-06	8.66e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—SULT1A1—breast cancer	5.75e-06	8.6e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GPX4—breast cancer	5.75e-06	8.6e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CDKN1B—breast cancer	5.7e-06	8.52e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—APRT—breast cancer	5.69e-06	8.5e-05	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—AKT1—breast cancer	5.63e-06	8.43e-05	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—KRAS—breast cancer	5.63e-06	8.41e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GSTA1—breast cancer	5.62e-06	8.4e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—IDH1—breast cancer	5.62e-06	8.4e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CASP3—breast cancer	5.58e-06	8.35e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—IL2—breast cancer	5.57e-06	8.33e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—NAT2—breast cancer	5.56e-06	8.31e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—IL6—breast cancer	5.55e-06	8.29e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CCND1—breast cancer	5.43e-06	8.13e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—JUN—breast cancer	5.42e-06	8.11e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CTNNB1—breast cancer	5.38e-06	8.05e-05	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PIK3CD—breast cancer	5.37e-06	8.02e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ESRRA—breast cancer	5.35e-06	8e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ANGPTL4—breast cancer	5.35e-06	8e-05	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—ALB—breast cancer	5.3e-06	7.92e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—MMP9—breast cancer	5.28e-06	7.89e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CDKN1A—breast cancer	5.26e-06	7.86e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PTEN—breast cancer	5.24e-06	7.84e-05	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—PIK3CA—breast cancer	5.17e-06	7.73e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—MAPK8—breast cancer	5.13e-06	7.67e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—AKT1—breast cancer	5.12e-06	7.65e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GPI—breast cancer	5.07e-06	7.58e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—HADHB—breast cancer	5.07e-06	7.58e-05	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—NOS3—breast cancer	5.07e-06	7.58e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—breast cancer	5.02e-06	7.51e-05	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—TP53—breast cancer	5e-06	7.48e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—DPYD—breast cancer	4.87e-06	7.29e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—MED12—breast cancer	4.87e-06	7.29e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—SRC—breast cancer	4.86e-06	7.27e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ALDH1A1—breast cancer	4.84e-06	7.23e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ALDH7A1—breast cancer	4.84e-06	7.23e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ALDOA—breast cancer	4.8e-06	7.17e-05	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—HRAS—breast cancer	4.78e-06	7.15e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—VEGFA—breast cancer	4.74e-06	7.08e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—STAT3—breast cancer	4.69e-06	7.01e-05	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PIK3CB—breast cancer	4.68e-06	6.99e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—NCOA3—breast cancer	4.66e-06	6.96e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—NME1—breast cancer	4.64e-06	6.93e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—UMPS—breast cancer	4.64e-06	6.93e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ADSL—breast cancer	4.64e-06	6.93e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—FHL2—breast cancer	4.64e-06	6.93e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PHGDH—breast cancer	4.64e-06	6.93e-05	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PTGS2—breast cancer	4.63e-06	6.93e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—SLC2A2—breast cancer	4.62e-06	6.91e-05	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—IL6—breast cancer	4.58e-06	6.85e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—breast cancer	4.58e-06	6.84e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—LDHB—breast cancer	4.55e-06	6.8e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—BRIP1—breast cancer	4.55e-06	6.8e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—HPSE—breast cancer	4.55e-06	6.8e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CPT1A—breast cancer	4.53e-06	6.77e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—MTR—breast cancer	4.53e-06	6.77e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ABCG2—breast cancer	4.53e-06	6.77e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—MAPK3—breast cancer	4.48e-06	6.7e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—HPGDS—breast cancer	4.44e-06	6.64e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—HBA1—breast cancer	4.41e-06	6.6e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—MYC—breast cancer	4.36e-06	6.52e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—TGFB1—breast cancer	4.35e-06	6.5e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ABCC1—breast cancer	4.31e-06	6.45e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—HMMR—breast cancer	4.31e-06	6.45e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GSTA3—breast cancer	4.31e-06	6.45e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GSTT1—breast cancer	4.31e-06	6.44e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ACHE—breast cancer	4.31e-06	6.44e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—EGFR—breast cancer	4.26e-06	6.37e-05	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—AKT1—breast cancer	4.22e-06	6.31e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PPARGC1B—breast cancer	4.17e-06	6.24e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CYP17A1—breast cancer	4.08e-06	6.1e-05	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PTEN—breast cancer	4.04e-06	6.04e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ENO1—breast cancer	4.04e-06	6.04e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PTGS1—breast cancer	4.04e-06	6.04e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—KRAS—breast cancer	4.03e-06	6.02e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—breast cancer	4.02e-06	6.02e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—ALB—breast cancer	3.97e-06	5.94e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CYP2D6—breast cancer	3.96e-06	5.92e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CA9—breast cancer	3.94e-06	5.89e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GSTA4—breast cancer	3.94e-06	5.89e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—NCOA2—breast cancer	3.89e-06	5.81e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GSTA2—breast cancer	3.84e-06	5.74e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GPX2—breast cancer	3.84e-06	5.74e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GPX4—breast cancer	3.79e-06	5.67e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—SULT1A1—breast cancer	3.79e-06	5.67e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—FASN—breast cancer	3.77e-06	5.64e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—BCHE—breast cancer	3.75e-06	5.61e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—SLC5A5—breast cancer	3.71e-06	5.54e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—IDH1—breast cancer	3.71e-06	5.54e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GSTA1—breast cancer	3.71e-06	5.54e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PIK3CA—breast cancer	3.7e-06	5.53e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—NAT2—breast cancer	3.66e-06	5.48e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—NQO1—breast cancer	3.58e-06	5.35e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—SLC2A1—breast cancer	3.58e-06	5.35e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—TP53—breast cancer	3.58e-06	5.35e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	3.51e-06	5.24e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CYP3A4—breast cancer	3.49e-06	5.22e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	3.47e-06	5.2e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CYP1B1—breast cancer	3.43e-06	5.13e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—HRAS—breast cancer	3.42e-06	5.12e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—HSP90AA1—breast cancer	3.37e-06	5.03e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—IL6—breast cancer	3.28e-06	4.9e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—NCOA1—breast cancer	3.28e-06	4.9e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—STK11—breast cancer	3.23e-06	4.83e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CYP19A1—breast cancer	3.23e-06	4.83e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—MED12—breast cancer	3.21e-06	4.81e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—DPYD—breast cancer	3.21e-06	4.81e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ALDOA—breast cancer	3.16e-06	4.73e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—NCOA3—breast cancer	3.07e-06	4.59e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—SLC2A2—breast cancer	3.05e-06	4.56e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—breast cancer	3.03e-06	4.53e-05	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—AKT1—breast cancer	3.02e-06	4.52e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—COMT—breast cancer	3e-06	4.49e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ABCG2—breast cancer	2.99e-06	4.47e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CPT1A—breast cancer	2.99e-06	4.47e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—MTR—breast cancer	2.99e-06	4.47e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GSTP1—breast cancer	2.99e-06	4.47e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—HMOX1—breast cancer	2.95e-06	4.4e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ITPR1—breast cancer	2.94e-06	4.39e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—HPGDS—breast cancer	2.93e-06	4.38e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—HBA1—breast cancer	2.91e-06	4.35e-05	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PIK3CA—breast cancer	2.85e-06	4.26e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ACHE—breast cancer	2.84e-06	4.25e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GSTT1—breast cancer	2.84e-06	4.25e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ABCB1—breast cancer	2.83e-06	4.23e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—TYMS—breast cancer	2.78e-06	4.15e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—NCOR1—breast cancer	2.74e-06	4.1e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PLA2G4A—breast cancer	2.74e-06	4.1e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GSTM1—breast cancer	2.74e-06	4.1e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CYP17A1—breast cancer	2.69e-06	4.02e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ENO1—breast cancer	2.66e-06	3.98e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PTGS1—breast cancer	2.66e-06	3.98e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—GPX1—breast cancer	2.63e-06	3.93e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CYP2D6—breast cancer	2.61e-06	3.9e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CYP1A1—breast cancer	2.6e-06	3.89e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ERCC2—breast cancer	2.58e-06	3.86e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—NCOA2—breast cancer	2.56e-06	3.83e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—FASN—breast cancer	2.49e-06	3.72e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—BCHE—breast cancer	2.48e-06	3.7e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—SLC5A5—breast cancer	2.45e-06	3.66e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—MTHFR—breast cancer	2.43e-06	3.63e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—NQO1—breast cancer	2.36e-06	3.53e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—SLC2A1—breast cancer	2.36e-06	3.53e-05	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—AKT1—breast cancer	2.33e-06	3.48e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CYP1B1—breast cancer	2.26e-06	3.39e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CAV1—breast cancer	2.24e-06	3.35e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—HSP90AA1—breast cancer	2.22e-06	3.32e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—NCOA1—breast cancer	2.16e-06	3.23e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	2.14e-06	3.2e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CYP19A1—breast cancer	2.13e-06	3.18e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—STK11—breast cancer	2.13e-06	3.18e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PIK3CG—breast cancer	2.04e-06	3.05e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—COMT—breast cancer	1.98e-06	2.96e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GSTP1—breast cancer	1.97e-06	2.95e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—HMOX1—breast cancer	1.94e-06	2.9e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ITPR1—breast cancer	1.94e-06	2.9e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ABCB1—breast cancer	1.86e-06	2.79e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—TYMS—breast cancer	1.83e-06	2.74e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—NCOR1—breast cancer	1.81e-06	2.71e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GSTM1—breast cancer	1.81e-06	2.71e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PLA2G4A—breast cancer	1.81e-06	2.71e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PIK3CD—breast cancer	1.79e-06	2.68e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ALB—breast cancer	1.77e-06	2.64e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—GPX1—breast cancer	1.73e-06	2.59e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CYP1A1—breast cancer	1.72e-06	2.57e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ERCC2—breast cancer	1.7e-06	2.54e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—NOS3—breast cancer	1.69e-06	2.53e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—MTHFR—breast cancer	1.6e-06	2.39e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PIK3CB—breast cancer	1.56e-06	2.34e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PTGS2—breast cancer	1.55e-06	2.31e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CAV1—breast cancer	1.48e-06	2.21e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PTEN—breast cancer	1.35e-06	2.02e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PIK3CG—breast cancer	1.34e-06	2.01e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PIK3CD—breast cancer	1.18e-06	1.77e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ALB—breast cancer	1.17e-06	1.74e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—NOS3—breast cancer	1.12e-06	1.67e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PIK3CB—breast cancer	1.03e-06	1.54e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PTGS2—breast cancer	1.02e-06	1.53e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PIK3CA—breast cancer	9.52e-07	1.42e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PTEN—breast cancer	8.9e-07	1.33e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—AKT1—breast cancer	7.78e-07	1.16e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PIK3CA—breast cancer	6.28e-07	9.39e-06	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—AKT1—breast cancer	5.13e-07	7.67e-06	CbGpPWpGaD
